Q1 Earnings Forecast for NKTR Issued By HC Wainwright

Nektar Therapeutics (NASDAQ:NKTR) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Tuesday, June 24th. HC Wainwright analyst A. He anticipates that the biopharmaceutical company will post earnings of ($3.00) per share for the quarter. HC Wainwright has a “Buy” rating and a $120.00 price target on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q3 2026 earnings at ($3.06) EPS.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.70) by ($0.60). Nektar Therapeutics had a negative return on equity of 329.54% and a negative net margin of 152.49%. The firm had revenue of $10.46 million during the quarter, compared to analysts’ expectations of $15.61 million. During the same quarter in the previous year, the firm earned ($2.70) earnings per share.

A number of other brokerages have also weighed in on NKTR. Wall Street Zen lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 14th. William Blair reissued a “market perform” rating on shares of Nektar Therapeutics in a research report on Monday, May 12th. Oppenheimer raised shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $90.00 price objective for the company in a research report on Friday, March 14th. Jefferies Financial Group raised shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and boosted their price objective for the company from $15.00 to $30.00 in a research report on Friday, April 11th. Finally, BTIG Research upped their target price on shares of Nektar Therapeutics from $60.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $76.43.

Nektar Therapeutics Stock Up 1.9%

Shares of NASDAQ NKTR opened at $29.68 on Thursday. Nektar Therapeutics has a twelve month low of $6.48 and a twelve month high of $37.38. The firm has a market cap of $368.33 million, a P/E ratio of -3.09 and a beta of 0.55. The company has a 50 day moving average of $11.19 and a 200 day moving average of $12.15.

Institutional Trading of Nektar Therapeutics

Hedge funds have recently made changes to their positions in the business. Two Sigma Securities LLC raised its position in Nektar Therapeutics by 56.3% in the 4th quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 9,958 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Nektar Therapeutics by 6.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 192,978 shares of the biopharmaceutical company’s stock valued at $180,000 after purchasing an additional 10,941 shares during the period. Northern Trust Corp lifted its position in Nektar Therapeutics by 0.9% during the fourth quarter. Northern Trust Corp now owns 1,414,984 shares of the biopharmaceutical company’s stock valued at $1,316,000 after purchasing an additional 12,826 shares during the period. ProShare Advisors LLC raised its position in shares of Nektar Therapeutics by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 50,277 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 16,543 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of Nektar Therapeutics by 26.5% in the fourth quarter. Wells Fargo & Company MN now owns 108,975 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 22,822 shares during the period. 75.88% of the stock is currently owned by hedge funds and other institutional investors.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.